225 related articles for article (PubMed ID: 33052749)
21. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.
De Backer W; Devolder A; Poli G; Acerbi D; Monno R; Herpich C; Sommerer K; Meyer T; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):137-48. PubMed ID: 20109122
[TBL] [Abstract][Full Text] [Related]
22. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
23. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.
Singh D; van den Berg F; Leaker B; Corradi M; Jabbal S; Collarini S; Mongelli V; Santoro L; Piccinno A; Biondaro S; Lipworth B
Br J Clin Pharmacol; 2019 Apr; 85(4):729-736. PubMed ID: 30586199
[TBL] [Abstract][Full Text] [Related]
25. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
[TBL] [Abstract][Full Text] [Related]
26. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
[TBL] [Abstract][Full Text] [Related]
27. Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease.
Pelaia C; Procopio G; Rotundo FL; Deodato MR; Ferrante Bannera A; Tropea FG; Cancelliere A; Vatrella A; Pelaia G
Ther Adv Respir Dis; 2023; 17():17534666231155778. PubMed ID: 36846944
[TBL] [Abstract][Full Text] [Related]
28. Small Airways, Big Problem: Extrafine beclomethasone/formoterol in asthma and chronic obstructive pulmonary disease.
Hasan A; Mukherjee P; Chhowala S; Lopez M; Chhajed PN
Lung India; 2021; 38(4):350-358. PubMed ID: 34259174
[TBL] [Abstract][Full Text] [Related]
29. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
Dean J; Panainte C; Khan N; Singh D
Respir Res; 2020 Dec; 21(1):323. PubMed ID: 33298062
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
Orlovic M; Magni T; Lukyanov V; Guerra I; Madoni A
Respir Med; 2022 Sep; 201():106934. PubMed ID: 35872377
[TBL] [Abstract][Full Text] [Related]
31. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
[TBL] [Abstract][Full Text] [Related]
32. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
[TBL] [Abstract][Full Text] [Related]
33. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma.
Kuna P; Jerzynska J; Martini M; Vele A; Barneschi I; Mariotti F; Georges G; Ciurlia G
Pharmacol Res Perspect; 2022 Aug; 10(4):e980. PubMed ID: 35733414
[TBL] [Abstract][Full Text] [Related]
35. Evolving to a single inhaler extrafine LABA/LAMA/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE).
Brusselle G; Himpe U; Fievez P; Leys M; Perez Bogerd S; Peché R; Vanderhelst E; Lins M; Capiau P;
Respir Med; 2023 Nov; 218():107368. PubMed ID: 37562659
[TBL] [Abstract][Full Text] [Related]
36. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):269-279. PubMed ID: 27209586
[TBL] [Abstract][Full Text] [Related]
37. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation.
Müller V; Gálffy G; Eszes N; Losonczy G; Bizzi A; Nicolini G; Chrystyn H; Tamási L
BMC Pulm Med; 2011 Jul; 11():40. PubMed ID: 21762500
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol.
Richeldi L; Piraino A; Macagno F; Micarelli G; Ingrassia E
Int J Chron Obstruct Pulmon Dis; 2021; 16():159-166. PubMed ID: 33536751
[TBL] [Abstract][Full Text] [Related]
39. A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD.
Ming SWY; Haughney J; Ryan D; Small I; Lavorini F; Papi A; Singh D; Halpin DMG; Hurst JR; Patel S; Ochel M; Kocks J; Carter V; Hardjojo A; Price DB
Int J Chron Obstruct Pulmon Dis; 2020; 15():3093-3103. PubMed ID: 33273812
[TBL] [Abstract][Full Text] [Related]
40. Effect of extrafine formulation of BDP/FF inhaler on asthma control, small airway function and airway inflammation among Mexican asthmatic patients. A retrospective analysis.
Díaz-García R; Flores-Ramírez G; Ramírez-Oseguera RT
Respir Med; 2020; 165():105932. PubMed ID: 32308205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
